Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence

Launched by RENJI HOSPITAL · May 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging method called 68Ga-FAPI PET/CT to see how well it can detect the return of ovarian cancer, particularly a type known as epithelial ovarian cancer. The trial is comparing this new imaging technique to a more commonly used one called 18F-FDG PET/CT. Researchers hope to find out if 68Ga-FAPI PET/CT is more effective in spotting cancer that may have come back after treatment.

To participate in this trial, women aged 18 to 80 who are suspected to have recurrent ovarian cancer may be eligible. Participants will need to have both imaging tests done within a week and should not have received any other treatments four weeks before the imaging. During the study, participants will undergo these two imaging scans, which are painless and non-invasive, to help determine the best treatment plan moving forward. It's important to note that pregnant women and those with serious health issues or who are unwilling to provide consent cannot take part in this trial.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • adult patients (age\>18 and\<80 years)
• • patients with clinically suspected recurrent ovarian cancer
• • patients who underwent paired 18F-FDG and 68Ga-FAPI PET/CT for the most proper treatment strategy within 1 week
• • patients who did not receive any other treatment 4 weeks before PET imaging
• Exclusion Criteria:
• • pregnant patients
• • patients with poor performance status
• • patients unwilling to provide written informed consent